Study of PMD-026 for worsening myelofibrosis
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia) that is in the chronic phase
- You have tried a JAK inhibitor (such as ruxolitinib) for at least 12 weeks, and it stopped working, caused side effects, or you couldn't tolerate it
- Your myelofibrosis is classified as intermediate-2 or high-risk (a measure of how advanced your disease is)
- You have an enlarged spleen (at least 450 cubic centimeters on imaging, or your doctor can feel it 5 centimeters below your ribs)
- You have at least 10 symptoms on a myelofibrosis symptom score (such as fatigue, night sweats, or itching)
- You are 18 years or older and have adequate organ function and blood counts
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a drug called interferon alfa-2b to the standard treatment ruxolitinib can help people with myelofibrosis. It may reduce spleen size and improve blood counts.
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
This trial tests two new medicines, selinexor and pacritinib, for people with myelofibrosis who have low blood counts and have not yet tried JAK inhibitor therapy. The goal is to see if this combination helps reduce spleen size and improve blood counts.
This trial tests a new drug called revumenib, which is being studied for people with myelofibrosis. Revumenib may help slow the disease and improve symptoms. The study has two parts: one for people who have already tried a JAK inhibitor, and one for those currently on a JAK inhibitor but still have active disease.
This trial tests an oral drug called tasquinimod for people with myelofibrosis that no longer responds to or cannot take a JAK inhibitor. The goal is to see if tasquinimod can help shrink an enlarged spleen and improve symptoms.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.